Navigation Links
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Date:11/12/2009

THE WOODLANDS, Texas, Nov. 12 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). Top-line results showed that treatment with one gram of LX1031 four times daily produced a statistically significant improvement in global assessment of relief of IBS pain and discomfort over the four-week dosing period as compared to placebo (p=0.0465). Improvements in global assessment parameters also corresponded with statistically significant improvements in stool consistency. Notably, increased clinical response correlated with a greater reduction in serotonin synthesis as reflected by measures of urinary 5-HIAA, a breakdown product of serotonin.

"Treatment with LX1031 reduced symptoms of IBS in this clinical trial, and holds promise for patients with this disease," said Dr. Brian Zambrowicz, chief scientific officer at Lexicon. "We believe the fact that the clinical benefit was correlated to the reduction in the 5-HIAA biomarker validates our therapeutic strategy of inhibiting TPH as a novel treatment option for patients with IBS. The overall safety and efficacy profile observed to date supports further development of this novel mechanism in IBS."

The Phase 2 clinical trial, which began at the end of December 2008, was a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1031 and its effects on symptoms associated with IBS. The study included 155 patients with either diarrhea-predominant IBS or mixed IBS. Two dose levels were evaluated: a 250 mg dose and a 1,000 mg
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Announces Completion of Public Offering of Common Stock
2. Lexicon Announces Pricing of Common Stock in Public Offering
3. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
4. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
6. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
10. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
11. WIFH Atlanta Announces Breakthrough Technique in Laser Hair Removal for Ethnic Skin Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
(Date:7/2/2015)... Wash. , July 2, 2015   BioLife Solutions ... and marketer of proprietary clinical grade cell and tissue ... a related cloud hosted biologistics cold chain management app ... today announced that Seattle Business Magazine has included ... to work for in Washington state ...
(Date:7/2/2015)... July 2, 2015 BGI announced today that ... Kong has been accredited by the American ... the first clinical next-generation-sequencing laboratory to receive the CAP ... highest standard in clinical laboratory practices. Complementary to the exiting ... process, and multiple ISO certifications, the CAP certification enables ...
Breaking Medicine Technology:BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 2BioLife Solutions Named One of the 100 Best Companies to Work For in Washington State 3BGI Receives Accreditation from the College of American Pathologists (CAP) 2
... Inc., a pioneer in the area of digital PCR, is ... to evaluate the capabilities of digital PCR and see the ... will start on Monday, September 12 in Boston and finish ... The QuantaLife ddPCR System claims to be the world,s most ...
... SILVER SPRING, Md., Aug. 26, 2011 The FDA ... ensuring the safety of their food and medical supplies ... week,s expected hurricane-related rain, possible flooding and power outages. ... The agency also reminds consumers that it is important ...
Cached Medicine Technology:QuantaLife™ Kicks Off Droplet Digital™ PCR Road Show 2FDA Hurricane Preparedness Checklist 2FDA Hurricane Preparedness Checklist 3FDA Hurricane Preparedness Checklist 4
(Date:7/2/2015)... ... 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... Lone Star State. The premium frozen yogurt chain was listed as #22 on the Inc. ... in the Village at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, ...
(Date:7/2/2015)... ... ... the recent report by JAMA Internal Medicine published on June 22, 2015, ... declared a war on obesity in the United States. , "Obesity is one of ... magnitude of this discovery. For that reason, I am declaring, along with my Health ...
(Date:7/2/2015)... ... 02, 2015 , ... When Walker Parking Consultants specified Kenall ... Minnesota, they knew it would save the university energy and maintenance costs. What ... total energy savings after installation was an impressive 89 percent, which resulted in ...
(Date:7/2/2015)... ... ... full swing, Americans are flocking to Canada’s many lakes to reel in their fair share ... and it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to ... a huge industry, and Americans make up the vast majority of anglers from outside of ...
(Date:7/2/2015)... ... ... LIFX ” was featured on NewsWatch as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... According to the U.S. Department of Energy, it’s very important to use energy-efficient light ...
Breaking Medicine News(10 mins):Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2
... increased over the past years with more than one-third ... alternative medicine. Alternative or complementary therapies include treatments such ... vitamins. ,Researchers in Boston compared the results ... National Health Interview Survey taken in 2002. Results showed ...
... disorder, where white blood cells attack fatty tissue surrounding nerve ... is twice as common in women as in men . ... with multiple sclerosis. Since MS causes muscle weakness and fatigue, ... of life, researchers designed an exercise program to develop ...
... in as little as two days of physical inactivity, the ... and other related diseases.// ,Researchers conducted a study in ... stayed inactive. When the rats stopped running for two days ... of sugar taken into the muscle in response to insulin ...
... children who have Duchenne muscular dystrophy (DMD) with the oral ... despite the side effects of the drug . Most patients ... teens or early 20s from respiratory failure or heart problems. ... questioned whether its side effects, which can range from weight ...
... carry a gene that produces a higher level of ... for stroke.// ,Researchers reviewed medical literature on homocysteine ... study results were observational in nature. A standard scientific ... looking at data on the link between homocysteine and ...
... disease who follow a heart-healthy diet and weight-loss regimen ... that raise HDL (high-density lipoproteins or "good" cholesterol) levels, ... patients younger than 76 with low HDL and known ... a heart-healthy diet and lost weight. However, results showed ...
Cached Medicine News:
... Electrohydraulic Lithotriptor combines efficient stone fragmentation, low ... a large, clear LED display, automatic probe ... according to probe size. In addition, the ... end-of-life, and can also regulate and control ...
Electrohydraulic Lithotripsy Probe for AEH-2 & AEH-3...
Short double-horn bridge for insertion of instruments...
Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha...
Medicine Products: